Sanofi has completed the filing of its 2025 Universal Registration Document with the French Financial Markets Authority (AMF) and submitted its Form 20-F to the U.S. Securities and Exchange Commission (SEC), fulfilling regulatory disclosure requirements on both sides of the Atlantic. The comprehensive filings contain the company's Annual Financial Report alongside detailed corporate governance disclosures and auditor information required under applicable regulations.
The documents encompass material business information including details on Sanofi's share buyback programs and sustainability initiatives, providing stakeholders with a complete picture of the pharmaceutical company's financial position, governance structure, and operational priorities for the fiscal year. These regulatory filings represent standard annual reporting obligations for companies listed on multiple exchanges and subject to both European and American securities regulations.
The simultaneous submission of both documents ensures Sanofi maintains compliance with dual-listing requirements and provides transparency to institutional and retail investors in key markets.